Streamlining Eylea Prior Authorization for Psychiatry and Other Diverse Workflows

While Eylea (aflibercept) is an anti-VEGF therapy indicated for ophthalmological conditions, and not a psychiatric medication, health systems frequently manage its complex buy-and-bill prior authorization alongside the distinct, high-volume prior authorization demands of their psychiatry departments. Klivira provides a unified platform to manage these disparate workflows.

Revenue cycle leaders and PA coordinators in integrated health systems face the challenge of managing a vast array of prior authorization requirements, from high-cost specialty drugs like Eylea to intricate behavioral health services. This necessitates a robust system capable of addressing the unique documentation, payer policies, and workflow constraints of each clinical domain. Klivira's platform is engineered to bring efficiency and compliance to this diverse operational landscape.

Eylea (Aflibercept) Prior Authorization: A Specialty Drug Overview

Eylea, an anti-VEGF intravitreal injection, is indicated for conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion. Its prior authorization pathway typically involves specialty drug approval processes and often falls under buy-and-bill workflows. This requires precise documentation of diagnosis, medical necessity, and sometimes prior treatment failures, managed by ophthalmology or retina specialists.

Navigating Psychiatry Prior Authorization Complexities

Psychiatry prior authorization presents a distinct set of challenges, often characterized by high-volume requests across various levels of care and specialty medications. Common PA-triggering categories include inpatient psychiatric admissions, partial hospitalization (PHP), intensive outpatient (IOP), residential treatment (especially for substance use disorder), and specialty psychiatric medications like long-acting injectables or REMS-restricted drugs such as esketamine. Additionally, procedures like ECT and TMS frequently require prior authorization.

Key Documentation Requirements for Psychiatric Services

  • DSM-5-TR diagnosis and severity documentation (e.g., PHQ-9, GAD-7, Beck scales).
  • ASAM Criteria documentation for substance use disorder (SUD) admissions across six dimensions.
  • Safety risk assessment, including suicidal or homicidal ideation, plan, and intent.
  • Documentation of prior level-of-care trials for residential or intensive outpatient services.
  • For TMS: detailed records of failed antidepressant trials (often 2-4 with adequate dose/duration).
  • For specialty injectables: diagnosis confirmation and prior oral medication trials, where applicable.

Operational Overlap: Managing Disparate PAs within a Single System

Even though Eylea is not a psychiatric medication, a comprehensive prior authorization platform must effectively manage both buy-and-bill specialty drug PAs and complex behavioral health PAs for an integrated health system. This operational intersection demands a system that can adapt to diverse payer policies, EMR documentation variances across specialties, and the need for centralized oversight. Klivira’s platform is designed to handle this breadth, ensuring that whether it's an anti-VEGF injection or a residential SUD admission, the PA process is streamlined.

Klivira's Unified Approach to Diverse Prior Authorization Needs

Klivira's platform provides a centralized solution for managing a wide spectrum of prior authorizations, including the distinct requirements for specialty drugs like Eylea and the intricate pathways for psychiatry. Our intelligent automation integrates with existing EMRs, connects to payer portals via X12 278 and ePA, and leverages a dynamic rules engine. For psychiatry, this includes ASAM-criteria-aware logic, parity-act flag-when-restrictive analysis, and concurrent-review workflows for inpatient/residential continued stays, alongside automation for TMS step-therapy documentation.

Frequently asked questions

Can psychiatrists prescribe Eylea?

No, Eylea (aflibercept) is an anti-VEGF medication specifically for ophthalmological conditions like wet AMD, DME, and retinal vein occlusion. It is prescribed and administered by ophthalmologists or retina specialists, not psychiatrists. However, an integrated health system may manage prior authorizations for both these distinct clinical areas.

How does Klivira handle prior authorizations for both specialty drugs like Eylea and complex behavioral health services?

Klivira's platform is designed to manage a broad range of prior authorization workflows. It uses a flexible rules engine to apply specific payer policies for specialty drugs like Eylea, including buy-and-bill processes, while also incorporating specialized logic for psychiatry, such as ASAM criteria, concurrent review for levels of care, and step-therapy documentation for treatments like TMS.

What are common denial reasons for psychiatric prior authorizations?

Common denial reasons in psychiatry include ASAM level mismatch (e.g., residential denied when ASAM supports a lower level of care), step therapy (insufficient antidepressant trials for TMS or oral trials for specialty injectables), and concurrent review denials for continued inpatient stay when severity criteria are no longer met. Parity-act violations and out-of-network treatment are also frequent issues.

Does Klivira integrate with EMRs for both ophthalmology and psychiatry documentation?

Yes, Klivira integrates with various EMRs via SMART on FHIR and other secure methods to pull necessary clinical documentation for prior authorization. This allows for seamless data flow, whether the documentation originates from an ophthalmology clinic for Eylea or a behavioral health department for psychiatric services, ensuring all required information is captured for submission.

What specific operational constraints does Klivira address for psychiatry PA?

Klivira addresses critical psychiatry PA constraints such as time-sensitive admission decisions, continuous concurrent review for inpatient/residential stays, and the need to flag potential parity-act violations. Our platform also supports documentation requirements for restricted-dispensing drugs like esketamine and automates step-therapy tracking for procedures like TMS.

Related coverage

Other eylea prior authorization by payer

Other eylea prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo